Praxis für HNO und Allergologie Dr. Yury Yarin
- Address
- Overbeckstraße 33, 01139 Dresden, Germany
Praxis für HNO und Allergologie Dr. Yury Yarin - Specialized ENT and Allergy Research Center
Praxis für HNO und Allergologie Dr. Yury Yarin is a leading clinical research center specializing in otolaryngology (ENT) and allergology. The practice demonstrates extensive expertise in conducting advanced clinical trials for allergic rhinitis, rhinoconjunctivitis, and chronic rhinosinusitis with nasal polyps. With a strong focus on immunotherapy and novel biologic treatments, the center plays a crucial role in evaluating cutting-edge therapeutic approaches for patients suffering from respiratory allergies and sino-nasal conditions.
- Allergen-specific immunotherapy trials for seasonal allergies (birch pollen, grass pollen) and perennial allergies (house dust mites)
- Biologic therapy research for chronic rhinosinusitis with nasal polyps (CRSwNP)
- Subcutaneous cluster-immunotherapy protocols with novel allergoid formulations
- Evaluation of combination therapies with intranasal corticosteroids
The center's research portfolio encompasses both Phase II-III clinical trials evaluating dose optimization and efficacy of various immunotherapy regimens, as well as studies of innovative biologic agents like lebrikizumab. The practice's clinical trial experience spans multiple therapeutic modalities including subcutaneous immunotherapy with mannan-conjugated allergoids and cluster-immunotherapy protocols, demonstrating commitment to advancing treatment options for patients with moderate-to-severe allergic diseases according to ARIA guidelines.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 62 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 61 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1ROXALL Medizin GmbH6trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Praxis für HNO und Allergologie Dr. Yury Yarin
lock Showing 1 of 16 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled Study of Subcutaneous Mannan-Conjugated Betula Pendula Pollen Allergoid in Birch Pollen-Induced Allergic Rhinitis | CCDRD Cooperative Clinical Drug Research and Development AG, ClinCompetence Cologne GmbH, Inmunotek S.L. | Phase III | Not Recruiting | Feb 2024 | Jun 2024 |
IMP list
lock Showing 1 of 62 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Histamine Dihydrochloride | 4 | Unknown | 2024-08-22 | 2026-06-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.